SCHEMBL742437

SCHEMBL742437

O=C(O)C(O)c1cccc([N+](=O)[O-])c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 1/20 0.56
TP53 P04637 1/20 0.54
LMNA P02545 3/20 0.53
TSHR P16473 2/20 0.53
GRM8 O00222 4/20 0.53
GRM4 Q14833 4/20 0.53
GRM6 O15303 3/20 0.53
L3MBTL1 Q9Y468 2/20 0.52
HTT P42858 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
MAPK1 P28482 1/20 0.52
CES2 O00748 1/20 0.51
CES1 P23141 1/20 0.51
MEN1 O00255 1/20 0.51
HPGD P15428 1/20 0.51
KMT2A Q03164 1/20 0.51
ALDH1A1 P00352 2/20 0.50
ALOX15 P16050 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11057509 1.00 ACP3 (0.56) ACP3TP53LMNATSHRGRM8
SCHEMBL5157317 1.00 ACP3 (0.56) ACP3TP53LMNATSHRGRM8
Alanine SCHEMBL11207143 0.91 GRM8 (0.53) ACP3TP53LMNATSHRGRM8
D-Alanine SCHEMBL11205686 0.91 GRM8 (0.53) ACP3TP53LMNATSHRGRM8
SCHEMBL5861774 0.84 ACP3 (0.58) ACP3TP53LMNATSHRGRM8
SCHEMBL13398884 0.84 LMNA (0.53) ACP3LMNATSHRGRM8GRM4
SCHEMBL11304497 0.83 ACP3 (0.56) ACP3TP53LMNATSHRGRM8
SCHEMBL31652701 0.83 ACP3 (0.56) ACP3TP53LMNATSHRGRM8
SCHEMBL11628390 0.82 CES2 (0.60) ACP3TP53LMNATSHRHTT
SCHEMBL2023789 0.82 TSHR (0.61) ACP3TP53LMNATSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2078200-A1 TEST FOR H. PYLORI INFECTION UCL Business PLC (GB) 2009-07-15 EP claimed
WO-2008038022-A1 TEST FOR H. PYLORI INFECTION UCL BUSINESS PLC (GB) 2008-04-03 WO claimed
EP-4455667-B1 DEVICE FOR DETECTING MOLECULES VISCERA TECH LTD (GB) 2025-08-13 EP disclosed
WO-2024223672-A1 DEVICE FOR DETECTING MOLECULES VISCERA TECHNOLOGIES LTD (GB) 2024-10-31 WO disclosed
EP-4455667-A1 DEVICE FOR DETECTING MOLECULES Viscera Technologies Ltd (GB) 2024-10-30 EP disclosed
CN-109467502-B Method for splitting mandelic acid compound enantiomer 湖南科技大学 2021-07-30 CN disclosed
CN-109467502-A A method of splitting almond acid compounds enantiomer 湖南科技大学 2019-03-15 CN disclosed
EP-1666473-B1 CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2013-01-02 EP disclosed
US-8138335-B2 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD (JP) 2012-03-20 US disclosed
US-20100029631-A1 CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2010-02-04 US disclosed
US-7601712-B2 Such as (1)-2-(4-chloro-3-((2-chloro-4-(((2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-ly)methoxy)benzoyl)amino)phenyl)-2-methylpropanoic acid; prostaglandin receptor agonists ONO PHARMACEUTICAL CO., LTD. (JP) 2009-10-13 US disclosed
EP-0816316-A1 PROCESS FOR PRODUCING 1,2-ETHANEDIOL DERIVATIVES NITTO CHEMICAL INDUSTRY CO., LTD. (JP) 1998-01-07 EP disclosed
US-5229510-A β-lactams useful in determining the amount of elastase in a clinical sample MERCK & CO., INC. (US) 1993-07-20 US disclosed
US-4467101-A CEPHALOSPORIN PRECURSORS CIBA-GEIGY CORPORATION (US) 1984-08-21 US disclosed
US-4374134-A Cephalosporin compounds with terminal aminocarboxylic acid groupings and anti-bacterial use thereof CIBA-GEIGY CORPORATION (US) 1983-02-15 US disclosed
US-4297489-A CEPHALOSPORINS BRISTOL-MYERS COMPANY (US) 1981-10-27 US disclosed
US-4172196-A CEPHALOSPORINS BRISTOL-MYERS COMPANY (US) 1979-10-23 US disclosed
US-4112228-A BACTERICIDES BRISTOL-MYERS COMPANY (US) 1978-09-05 US disclosed
US-3985738-A ANTIBACTERIAL AGENTS BRISTOL-MYERS COMPANY (US) 1976-10-12 US disclosed
US-3969401-A ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC WILLIAM H. RORER, INC. (US) 1976-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029631-A1 CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT GPR17, CYSLTR1, KIT ACP3 647/4885TP53 1983/4885LMNA 4266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.